Loading clinical trials...
Loading clinical trials...
A Phase 2 Study to Assess the Efficacy and Safety of TGR-1202 (Umbralisib) Monotherapy in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma
Conditions
Interventions
Umbralisib
Locations
4
United States
TG Therapeutics Investigational Trial Site
Washington D.C., District of Columbia, United States
TG Therapeutics Investigational Trial Site
Boston, Massachusetts, United States
TG Therapeutics Investigational Trial Site
Hackensack, New Jersey, United States
TG Therapeutics Investigational Trial Site
New York, New York, United States
Start Date
November 30, 2017
Primary Completion Date
February 15, 2022
Completion Date
February 15, 2022
Last Updated
June 23, 2023
NCT06149286
NCT07387471
NCT05006716
NCT06026319
NCT06510491
NCT01804686
Lead Sponsor
TG Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions